Valavir film-coated tablets 500 mg blister 10 pcs.

Active ingredient: valaciclovir;

1 tablet contains valacyclovir hydrochloride 556 mg, equivalent to valacyclovir 100% anhydrous substance 500 mg;

Excipients: microcrystalline cellulose (101), povidone, colloidal anhydrous silica, crospovidone, magnesium stearate;

Shell composition: Sepifilm 050 (methylhydroxypropylcellulose, microcrystalline cellulose, acetylated (or ester acetates) mono- and diglycerides), candurin.

Valavir is contraindicated in patients with hypersensitivity to valacyclovir, acyclovir, or any component of the drug.

Treatment of herpes zoster: adults should be prescribed 1000 mg (2 tablets) of Valavir 3 times a day for 7 days.

Treatment of infections caused by the herpes simplex virus. Patients with normal immunity (adults): 500 mg (1 tablet) of the drug 2 times a day.

Pregnant women

Can only be used when the potential benefit of treatment for the mother outweighs the possible risk to the fetus.

Children

It is used in children from 12 years of age to prevent cytomegalovirus infection and disease.

Drivers

With caution.

Symptoms. Acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, decreased mental capacity, and coma, have been reported with valaciclovir overdose. Nausea and vomiting may occur. Caution should be exercised to avoid accidental overdose. Many cases of overdose have been associated with the use of the drug in patients with renal insufficiency and in elderly patients in whom the dose was not reduced accordingly.

Treatment: Patients should be closely monitored for signs of toxicity. Hemodialysis significantly accelerates the removal of acyclovir from the blood and may therefore be considered the optimal treatment for symptomatic overdose.

Among the more serious adverse reactions were reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, acute renal failure, and neurological disorders.

No clinically significant forms of interaction were identified.

Patients receiving higher doses of Valavir (4 g or more per day) should be careful when co-administering drugs that compete with acyclovir for excretion routes, as this may lead to an increase in the plasma levels of one or both drugs and their metabolites. When used simultaneously with mycophenolate mofetil (an immunosuppressive drug used after organ transplantation), the plasma levels of acyclovir and the inactive metabolite of mycophenolate mofetil increase.

Caution should also be exercised (with monitoring of changes in renal function) when simultaneously prescribing high doses of Valavir (4 g or more) and other drugs that affect renal function (e.g. cyclosporine, tacrolimus).

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life – 3 years.